Mersana Therapeutics

NASDAQ: MRSN
Developing antibody-drug conjugates for cancer treatment.

F-Prime Team

Sector

Life Sciences

Category

Therapeutics

Location

Cambridge, MA

Initial Investment

2005
Developing antibody-drug conjugates for cancer treatment.

Mersana Therapeutics (NASDAQ: MRSN) has its lead product candidate, XMT-1536, in clinical trials in patients with tumors expressing NaPi2b, including ovarian cancer, NSCLC, and other cancers. In addition, multiple partners are using Mersana’s platform to advance their ADC pipelines.